BeOne Medicines AG (6160.HK)
Develops cancer drugs including blood cancer treatments and immunotherapies for patients worldwide.
197.80+0.01%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+11.8%
The outlook
BeOne Medicines trades at 197.8 with strong analyst consensus backing the stock—the average price target sits roughly 30% above current levels. The stock sits well above its 50- and 200-day moving averages and sits midway through its 52-week range, showing steady upward positioning. The company carries a high trailing P/E of 73.8, reflecting market expectations for growth.
What’s behind the score
Analyst consensusStrong Buy — 1.2 avg of 15 analysts
Price trendAbove its 50- & 200-day averages
52-week range59% of the way from its 52-week low to high
Price targetAvg target +30% vs current price
Analyst price target
~12-month · 15 analysts256.64average target+29.7% vs now
Now 197.80
Low 212.62High 298.46
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$266.79B
52-wk high
229.40
52-wk low
153.00
50-day avg
176.50
200-day avg
188.25
Trailing P/E
73.8